Results 101 to 110 of about 7,402 (202)

Darunavir/cobicistat/emtricitabine/tenofovir alafenamide in treatment-naïve patients with HIV-1: subgroup analyses of the phase 3 AMBER study

HIV Research & Clinical Practice, 2019
Background: The once-daily, single-tablet regimen darunavir/cobicistat/emtricitabine/tenofovir alafenamide (D/C/F/TAF) 800/150/200/10 mg is approved for the treatment of HIV-1 infection.
Bruce Rashbaum, Christoph D. Spinner, Cheryl McDonald, Cristina Mussini, John Jezorwski, Donghan Luo, Erika Van Landuyt, Kimberley Brown, Eric Y. Wong   +8 more
doaj   +1 more source

Switch to bictegravir/emtricitabine/tenofovir alafenamide in people living with HIV aged 65 years or older: BICOLDER study – IMEA 057

Journal of Infection and Public Health
Background: Polymedication and comorbidities are frequent in aging people with HIV (PWH) and often associated with elevated incidences of adverse events (AEs) and drug-drug interactions (DDIs).
Minh P. Lê, Clotilde Allavena, Véronique Joly, Lambert Assoumou, Valentina Isernia, Faiza Ajana, Didier Neau, Diane Descamps, Charlotte Charpentier, Aïda Benalycherif, Bao Phung, Gilles Peytavin, Roland Landman   +12 more
doaj   +1 more source

Pharmacokinetic interaction between single and multiple doses of darunavir, in combination with cobicistat or ritonavir, and single-dose dabigatran etexilate in healthy adults

AAPS Open
Objective Darunavir (DRV) is a P-glycoprotein (P-gp) inhibitor. Dabigatran etexilate, prodrug of the anticoagulant dabigatran, is a P-gp probe substrate. This study evaluated the effect of single and multiple doses of DRV, coadministered with cobicistat (
Sandy Van Hemelryck, Erika Van Landuyt, Jay Ariyawansa, Martyn Palmer, Martine J. C. Kothe, Caroline Pollefliet   +5 more
doaj   +1 more source

HIV Viral Rebound Due to a Possible Drug–Drug Interaction between Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide and Calcium-Containing Products: Report of 2 Cases

Journal of the International Association of Providers of AIDS Care, 2019
Elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide (E/C/F/TAF) is a potent fixed-dose, once-daily regimen for HIV-1 treatment and has rare emergence of drug resistance.
S. Lena Kang-Birken PharmD, Dena El-sayed MD, John Prichard MD   +2 more
doaj   +1 more source

Análisis de la evolución de las causas de discontinuación del tratamiento antirretroviral en práctica real durante una década [PDF]

, 2019
En la actualidad el virus de la inmunodeficiencia humana (VIH) sigue siendo un problema de salud a nivel mundial. Cuando estamos infectado por el VIH, este se replica en nuestro organismo pudiendo generar la enfermedad, síndrome de la inmunodeficiencia ...
Villegas Rodríguez, Ana
core  

Pulmonary hypertension in AIDS/HIV infection: a rare disease [PDF]

, 2016
A Hipertensão pulmonar (HTP) é uma patologia rara mas que condiciona elevada morbilidade e mortalidade. É conhecida a sua associação com o Vírus da Imunodeficiência Humana (VIH), mas muitos dos mecanismos implicados na sua patogénese bem como o ...
Cardoso, C, Pacheco, P, Trigo, D
core  

Dolutegravir and elvitegravir plasma concentrations following cessation of drug intake [PDF]

, 2015
Amara, Alieu, Back, David, Boffito, Marta, Elliot, Emilie, Else, Laura, Jackson, Akil, Khoo, Saye, Moyle, Graeme, Owen, Andrew   +8 more
core   +1 more source

Darunavir/Cobicistat [PDF]

, 2020
openaire   +1 more source

Long-term effectiveness of unboosted atazanavir plus abacavir/lamivudine in subjects with virological suppression: A prospective cohort study [PDF]

, 2016
Effectiveness data of an unboosted atazanavir (ATV) with abacavir/lamivudine (ABC/3TC) switch strategy in clinical routine are scant.We evaluated treatment outcomes of ATV + ABC/3TC in pretreated subjects in the EuroSIDA cohort when started with ...
Beniowski, M, Cozzi-Lepri, A, Duvivier, C, Edwards, S, EuroSIDA Study,, Falconer, K, Hassoun, G, Kuznetsova, A, Kuzovatova, E, Laut, K, Llibre, JM, Losso, M, Maltez, F, Mitsura, V, Mocroft, A, Paredes, R, Pedersen, C, Ristola, M, Stellbrink, HJ, Szlavik, J, Vullo, V   +20 more
core  

Prevalence of recreational drug use is indiscriminate across antiretroviral regimens of differing drug-drug interactions among MSM. [PDF]

, 2016
Daskalopoulou, M, Lampe, FC, Phillips, AN, Rodger, AJ, Speakman, A   +4 more
core   +1 more source